"
Team:Imperial College London/Drylab/Protein Production
From 2009.igem.org
(Difference between revisions)
(→Model for drug protein enzyme kinetics) |
(→Model for protein drug production:) |
||
| Line 8: | Line 8: | ||
* In the absence of IPTG, LacI represses the production of the drug (Cellulase or PAH) | * In the absence of IPTG, LacI represses the production of the drug (Cellulase or PAH) | ||
* When IPTG is introduced, the LacI repressing pathway is “de-repressed”, and some output protein is produced. | * When IPTG is introduced, the LacI repressing pathway is “de-repressed”, and some output protein is produced. | ||
| - | [[Image:II09_NoIPTG_yesIPTG.jpg|350px| | + | [[Image:II09_NoIPTG_yesIPTG.jpg|350px|right]] |
<!-- [[Image:m1.fgc.JPG | 400px.jpg]]--> | <!-- [[Image:m1.fgc.JPG | 400px.jpg]]--> | ||
Revision as of 12:08, 18 September 2009
Introduction
This module consists of producing the drug protein of interest. In order to describe the function of the module, two models have been developed.
Model for protein drug production:
Based on the Genetic circuit, a LacI-IPTG inducible promoter is responsible for kickstarting the production of the drug.
- In the absence of IPTG, LacI represses the production of the drug (Cellulase or PAH)
- When IPTG is introduced, the LacI repressing pathway is “de-repressed”, and some output protein is produced.
Our goals
The modelling aims to provide an overview and better understanding of the M1 system’s function by:
- Characterizing the system.
- Modeling to account for several factors that may reduce/hinder the production of the protein drug such as:
- Lac promoter leakiness
- IPTG toxicity
- Stability of output protein
This module is an integral part of the design, as large-scale commercialization of the drug of interest depends on finding the optimal conditions for protein production. This model has also helped the Wetlab to plan some of the experiments.
